Evidence map›Paper›PMID 42180381›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Diverse mediators of cancer predisposition uncovered by germline whole genome sequencing of unexplained familial cancers.

Noah Fields, Seunghun Han, Wenbin Mei, Erin Shannon, Ryan Buehler, Deborah Neklason, Erica Pimenta, Junne Kamihara, Judy Garber, Riaz Gillani and 4 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Noah FieldsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0008-7650-9117
Seunghun HanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wenbin MeiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9906-0916
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ryan BuehlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0005-4798-1365
Deborah NeklasonUtah Center of Genetic Discovery, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-4546-7080
Erica PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9684-6486
Junne KamiharaHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-2852-7387
Judy GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9449-3982
Riaz GillaniCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0001-8643-2725
Saud AlDubayanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9062-3399
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ryan L CollinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1268-9995
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444

Funding

Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI MATTHEW L FREEDMAN · 2023 to 2026
$12.0M
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney CancerR01CA278980 · NCI · DANA-FARBER CANCER INST · PI Eliezer M Van Allen · 2024 to 2026
$2.1M
Dissecting the Role of Germline Genetics in RAS-Driven CancersR00CA286805 · NCI · DANA-FARBER CANCER INST · PI Ryan Lewis Collins · 2025 to 2026
$436k
Dissecting the Role of Germline Genetics in RAS-Driven CancersK99CA286805 · NCI · DANA-FARBER CANCER INST · PI COLLINS, RYAN LEWIS · 2024 to 2025
$327k
NCI NIH HHS K99 CA286805NCI NIH HHS P50 CA272390NCI NIH HHS R00 CA286805NCI NIH HHS R01 CA278980
6 · The paper itself

Abstract

Cancer frequently clusters in families due to shared environment and genetics. However, many familial cancer cases lack a clinically recognized pathogenic germline variant (PGV). We analyzed germline genomes and family history from 2,726 individuals without a PGV in the All of Us Research Program, including 1,496 cases across 18 cancer types with extensive family history and 1,230 family history-negative, cancer-free controls. We identified allelic series of rare structural variants inactivating

Identifiers

PMID42180381
PMCPMC13193157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.